- Home
- PIII vs NRSN Comparison
PIII vs NRSN Comparison
Compare PIII & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- NRSN
- Stock Information
- Founded
- PIII 2015
- NRSN 2017
- Country
- PIII United States
- NRSN Israel
- Employees
- PIII N/A
- NRSN N/A
- Industry
- PIII Medical/Nursing Services
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- NRSN Health Care
- Exchange
- PIII Nasdaq
- NRSN Nasdaq
- Market Cap
- PIII 30.8M
- NRSN 26.0M
- IPO Year
- PIII N/A
- NRSN 2021
- Fundamental
- Price
- PIII $8.89
- NRSN $0.99
- Analyst Decision
- PIII Buy
- NRSN Hold
- Analyst Count
- PIII 2
- NRSN 1
- Target Price
- PIII $16.25
- NRSN N/A
- AVG Volume (30 Days)
- PIII 17.6K
- NRSN 130.1K
- Earning Date
- PIII 05-07-2025
- NRSN 04-07-2025
- Dividend Yield
- PIII N/A
- NRSN N/A
- EPS Growth
- PIII N/A
- NRSN N/A
- EPS
- PIII N/A
- NRSN N/A
- Revenue
- PIII $1,500,455,000.00
- NRSN N/A
- Revenue This Year
- PIII N/A
- NRSN N/A
- Revenue Next Year
- PIII $6.41
- NRSN N/A
- P/E Ratio
- PIII N/A
- NRSN N/A
- Revenue Growth
- PIII 18.48
- NRSN N/A
- 52 Week Low
- PIII $7.00
- NRSN $0.51
- 52 Week High
- PIII $40.50
- NRSN $1.50
- Technical
- Relative Strength Index (RSI)
- PIII 49.44
- NRSN 44.13
- Support Level
- PIII $8.36
- NRSN $0.97
- Resistance Level
- PIII $10.19
- NRSN $1.04
- Average True Range (ATR)
- PIII 0.97
- NRSN 0.09
- MACD
- PIII 0.06
- NRSN 0.00
- Stochastic Oscillator
- PIII 59.25
- NRSN 57.04
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.